Objective: To identify a risk profile for harmful medication errors in the neonatal intensive care unit (NICU).
Introduction
Since the release of the Institute of Medicine reports 'To Err Is Human' and 'Crossing the Quality Chasm: A New Health System for the 21st Century,' efforts have been made to further establish centralized reporting systems to understand the factors involved in medication errors. [1] [2] [3] [4] [5] [6] [7] Medication errors are common in pediatrics and, in particular, the neonatal intensive care unit (NICU). 7, 8 Errors with the potential to cause harm are eight times more likely to occur in the NICU as compared with adult settings in the hospital. 8 Moreover, medication errors comprise 47% of medical errors submitted to the Vermont Oxford Network's NICQ.org voluntary reporting system. 7 With a birth rate of 14.3 per 1000 persons in the United States and admission rates to NICUs as high as 6.6%, the repercussions of NICU medication errors can be considerable. [9] [10] [11] Neonates are a particularly vulnerable population and may be at further risk of harm from medication errors because of changing body size, weight-based dosages, off-label drug usage, availability of stock solutions in a variety of concentrations, inability to communicate with providers, and changing developmental systems affecting drug absorption, distribution, metabolism, and excretion. [12] [13] [14] [15] [16] [17] [18] For example, the necessary calculations involved in the ordering of medications and in the dilution of stock drugs in the NICU place these patients at risk for harm from 10-to 100-fold dosing errors. 19 Nevertheless, the understanding of medication errors affecting the care of the neonate is in its early stages, thus hampering efforts to identify targets for intervention in preventing these errors.
Since 1995, the Institute for Safe Medication Practices (ISMP) has made efforts to identify drugs most likely to cause harm to adult patients and has termed these drugs 'High-Alert Medications.' In 2005, ISMP established an updated list of 33 drugs and drug categories considered to be high-alert medications. 20 To our knowledge, there are no reports of the risk of harm from ISMP High-Alert Medication use in neonates in the literature to date.
The objective of our study is to further expand our knowledge of medication errors that affect the care of the neonate by reviewing medication errors reported to MEDMARX with the goal of identifying a risk profile for harmful medication errors in the NICU. We hypothesize that infants in the perinatal period and NICU patients who were prescribed ISMP High-Alert Medications are more likely to have medication errors reported as having resulted in harm to the patient.
Methods
Data source: United States Pharmacopeia MEDMARX reporting system The United States Pharmacopeia is an independent, internationally recognized, science-based public health organization and is the official public standards-setting authority for medicines manufactured and sold in the United States. 21 In 1998, United States Pharmacopeia introduced MEDMARX as an anonymous, confidential, de-identified, Internet-accessible medication error-reporting program. Data are collected locally and stored in a central data repository. As of January 2005, MEDMARX included 616 hospitals from all 50 states.
Data and variables
MEDMARX uses the definition of a medication error established by the National Coordinating Council for Medication Error Reporting and Prevention (NCC MERP), an independent body composed of 22 national organizations. 22 . A medication error is defined as 'any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the health care professional, patient, or consumer. Such events may be related to professional practice, health care products, procedures, and systems, including prescribing; order communication; product labeling, packaging, and nomenclature; compounding; dispensing; distribution; administration; education; monitoring; and use.' 22 MEDMARX also uses the NCC MERP taxonomy for data collection and the Index for categorizing medication errors. 22 Good inter-rater agreement (k ¼ 0.61) has been reported for MEDMARX users. 23 Each error report is standardized and provides information regarding the error's timing, location, error category, node, cause, medication involved, and error type. Facility characteristics captured include bed size, number of doses delivered, ownership, type of facility, and degree of pharmacist availability. Definitions for error categories 22 are listed in Table 1.  Variables used in MEDMARX are listed in Supplementary Appendix  A and Table 2 . Some data fields within the error reports are singlepick lists (error category and error node), and some are multiselect pick lists, allowing users to choose and enter as many items as they believe apply (error cause, error type, and medication involved).
A key driver for the types of information that are reported in MEDMARX is the error category variable. With increasing levels of harm, increasingly more data fields are required to be completed. For example, error categories A and B, the two lowest categories of error, do not require reporting of patient age, whereas patient age is required for all categories of error that reach the patient (C and above). Patient gender is always an optional field. For these reasons, there are more error reports coded as error Category A and B with unknown age and gender. Additionally, between 1998 and 2004, MEDMARX underwent a number of changes in required data fields as the concept of error reporting matured.
Analysis
We conducted a retrospective cross-sectional study on NICU medication error reports submitted to MEDMARX between 1 January 1999, and 31 December 2005. For error type, response choices were grouped into categories involving similar concepts, as defined by our research team. For example, under error type response choices of deteriorated product and expired product were combined into one category. For error cause, the pick-list choices were grouped into a modified version of the NCC MERP error cause categories developed by the research team ( Table 2) . 25 The significance of associations across categorical variables was tested with the Rao-Scott modified w 2 test to account for the clustering of medication error reports by facility. 26 The study was granted exemption from the Johns Hopkins University Institutional Review Board. Classified by similar concept.
Results

Study population
A total of 6749 NICU medication error reports were submitted by 163 facilities to MEDMARX during the study period. Patient and facility characteristics are shown in Table 3 .
Error categories
The majority of errors were Category C errors ( Figure 1 ). Potential errors (Category A) comprised 7% (420/6749) of the total number of submitted records. Twenty-four percent of actual errors (1529/6329) did not reach the patient (Category B). Seventy-two percent (4556/6329) of actual errors did not result in harm to the patient (Categories C-D). Four percent of actual errors (244/6329) resulted in permanent harm, necessity to provide an intervention to sustain life, or patient death (Categories E-I).
A small proportion of all harmful errors (Categories E-I) resulted in fatality (0.4%, 1/244). Table 5 .
Outcomes and actions taken after medication errors Of the 1788 reports that provided information regarding patient outcomes, the majority indicated that the patient needed increased Fentanyl drip was mixed at 10 mcg per ml and ordered to be run at 1 mcg h À1 . Medication was run at 1 ml h
À1
Furosemide
The furosemide dose for a baby was changed from once daily to twice daily. The medication was only given once daily for 3 days. The patient developed progressive congestive heart failure. Discharge was delayed Gentamicin Order written to continue antibiotics for a 14-day course. Antibiotics stopped on day 6. On day 12, patient had a set back Gentamicin Gentamicin and vancomycin were ordered for a septic patient. The floater nurse had difficulty locating the medication, which had been sent to the main unit of the floor. The unit secretary had placed the medications in the refrigerator, which prolonged the search. The medications were finally hung 4 h after they were ordered Indomethacin A dose of indomethacin 0.7 mg was ordered and administered twice to a preterm infant before it was discovered that the dose should have been 0.07 mg Morphine a Morphine 0.7 given (intended to be 0.07 mg). Five minutes after the medication was infusing, the patient 0 s oxygen saturation and heart rate dropped. The patient required ventilation and a dose of narcan. The morphine order was discontinued and changed later to fentanyl Vecuronium a Vecuronium 15 mg per 50 ml ordered at 1 ml h À1 . Fentanyl 300 mcg per 50 ml at 5 ml h À1 ordered. The rates on the drips were reversed. Recognized after 35 min H: An error occurred that required an intervention necessary to sustain life monitoring or hospitalization (40.9%), drug therapy changed or initiated (31.8%), or increased diagnostic testing (21.8%). Airway compromise or resuscitation was reported in 1.3% of cases. Examples of patient outcomes included the necessity for checking drug or glucose levels more frequently than required, intubating and ventilating patients who otherwise did not need these interventions, and prolonged hospital stays because of drug omissions and changes in the clinical status of the patients as a result of the error.
Of the 2706 reports that included information regarding actions taken as a result of the error, 48% of cases informed the staff who made the initial error, and 17.5% of cases informed other staff also involved in the error. The patient's physician was informed of the error in 8.7% of cases, and the patient's caregiver was informed in 2.8% of cases. Education and training was provided in 12.3% of cases, and policy and procedure modification was reported in 1.2% of cases.
Medications involved in errors
A total of 342 different medications were identified by the error reports ( Table 6 ). The majority of reports (91.8%) cited only one medication; 7.1% involved two medications; 1.1% included three or more medications. ISMP High-Alert Medications were cited in 1487 (22.0%) reports. Total parenteral nutrition (TPN) was the most frequently cited (n ¼ 410) ISMP High-Alert Medication, followed by fat emulsions (n ¼ 351), and fentanyl (n ¼ 169). Electrolytes, caloric, and water balance agents (28.1%), anti-infective agents (26.7%), and central nervous system agents (14.5%) were the most frequently reported AHFS classification system categories. The most frequently cited drugs were gentamicin (8.8%), ampicillin (5.6%), TPN (5.5%), and fat emulsions (4.7%).
Risk factors for harmful medication errors
There was no association between age and reported medication errors that resulted in harm (Table 7 , P ¼ 0.11). Factors that were more likely to result in harmful medication errors included use of ISMP High-Alert Medications, errors occurring in the prescribing phase of medication processing, or equipment/delivery device failures (Pp0.05). No other causes of error were significantly related to harm. Errors occurring in the transcribing and documenting phase were less likely to result in harm (P<0.01).
Discussion
This study is both the largest analysis of NICU medication errors to date, and to our knowledge, the first to show that use of ISMP High-Alert Medications is a risk factor for harm in the NICU. Additional risk factors for harm also emerge in this study and include errors that begin in the prescribing phase of medication use and failures in equipment and delivery devices. Collectively, these factors have begun to lay the groundwork for a risk profile for harmful medication errors in the NICU.
In addition, this study reveals that although the majority of reported medication errors do not result in harm to the NICU patient, medication errors are common in this clinical setting. In this analysis, the bulk of medication errors occur in the administering phase of medication processing, and human factors are the most common cause of error. Furthermore, electrolytes, caloric, and water balance agents and anti-infective agents constitute more than half of the medication categories identified in the error reports, and gentamicin and ampicillin are the most commonly identified medications. TPN, fat emulsions, and fentanyl, which are also ISMP High-Alert Medications, are on the list of the top five most commonly named medications.
The findings of this study are consistent with those conveyed by Suresh et al. 7 Both studies highlight the large number of administering errors that occur in the NICU and how human factors surface as the most frequent cause and contributory factor to medication errors. Harm scores, however, differ between the two studies. Suresh et al. found that approximately 27% of reported errors resulted in harm (categorized as minor harm, serious harm, or fatality). Our analysis, however, finds that 4% of reported medication errors result in harm. This discrepancy likely reflects the use of different harm definitions and categories between the studies, as well as possible differences in the propensity to report 'near misses.' In addition, our study examines reports that are exclusive to the NICU and focuses purely on medication error reports. It does not include other medical errors or involve other locations that provide care for neonates such as nurseries, stepdown units, delivery rooms, or emergency rooms as was the case in the Vermont Oxford Network study. Furthermore, our report uses a modified NCC MERP classification system as opposed to having errors categorized solely by experts in the field of safety.
Our findings are also consistent with earlier studies that have highlighted anti-infective, analgesic/sedative, and electrolytic/fluid agents as the most common drugs involved in pediatric, and now specifically, NICU medication errors. 8, 15, 18, 27 Our results likely reflect the frequent use of these medications in the NICU. One definition of risk indicates that risk is directly proportional to frequency of occurrence and to harm. 18 Accordingly, attention should be paid to those medications that are used regularly and that have narrow therapeutic windows. Interestingly, four of the top five medications identified in this report have narrow therapeutic windows relative to other drugs. For instance, TPN and fat emulsions have been shown to predispose NICU patients to harm from electrolyte imbalances and hypertriglyceridemia. [28] [29] [30] Given the frequent use and harm potential, TPN and fat emulsions have been targets for intervention in the NICU. 31 On the contrary, efforts to prevent harm from aminoglycosides such as gentamicin and opiates such as fentanyl have not received as much attention in the neonatal population. Opiates run a 6 to 8% risk for respiratory depression in the neonate, 32 and aminoglycosides have serious side effects such as nephrotoxicity and ototoxicity. Overdoses of these medications or improper monitoring protocols have the potential for devastating outcomes including death. 33 Despite improvements in the delivery of continuous intravenous infusion medications, 34 more work is needed to establish guidelines for their use. Surprisingly, age is not a significant risk factor for harm in this study. These results suggest that harmful errors may be a result of system failures as opposed to the underlying medical illness or changing physiology of the NICU patient as depicted by chronological age alone. 32 Other clinical data required to interpret patient age in the NICU such as gestation and birth weight is needed to help clarify this issue. Last but not least, our data suggest that there may be a protective effect of transcribing and documenting errors. One explanation for this finding is that these errors are not as likely to reach the patient because of various checks-and-balances in the medication processing system. Interestingly, stress and workload is the least cited error cause in this study suggesting that underreporting of these types of errors may be present in MEDMARX. In addition, very few error reports cited that errors were reported to caregivers and patients, thus underscoring that a culture of non-disclosure of errors may be present in the health-care system. Alternatively, as majority of reporters are often nursing staff, the nursing staff may have been unaware of disclosure conversations between the physician staff and the patients and families. However, more information on facility and staffing characteristics is needed to interpret these findings.
MEDMARX has limitations. [35] [36] [37] [38] [39] [40] First, errors are voluntarily reported and hence not representative of all medication errors. More complete reporting of all categories of errors, such as Category A and B medication errors, could shift the distribution of the reported errors. In addition, because total numbers of doses dispensed are not available, it is not possible to calculate error rates. Nevertheless, occurrence data remain a good way to identify trends. 40 Second, the majority of reports were made by nurses. This characteristic potentially skews the data toward administering errors. Even so, the nursing perspective provides information regarding medication errors undetectable by other methodologies. 18 Third, patient descriptor variables and facility characteristics are limited in MEDMARX. For example, had more patient characteristics such as gestational age and birth weight been collected, more risk factors for harmful medication errors could have been investigated and insight into the lack of significance of patient age for harm been gained. Moreover, information such as nursery level, number of annual deliveries, and number of NICU beds would have been helpful in characterizing the settings in which the various errors occurred. Indeed, the majority of NICUs reporting errors in this study were part of community and general hospitals, reducing the generalizability to other health-care settings such as academic NICUs. We recommend that these variables be added to reporting systems. And finally, although a good inter-rater agreement in MEDMARX has been established, 23 the definitions of the classification system are still subject to interpretation by the reporter, which can lead to misclassification of error data.
According to Leape, successful reporting systems are responsive and provide expert analysis and timely feedback. 41 Toward this aim, our study has identified several targets for intervention in preventing harmful medication errors in the NICU. First, our study calls for more work on the delivery and monitoring of ISMP HighAlert Medications as well as on the most frequently cited medications in NICU error reports such as aminoglycosides and opiates. Second, our study indicates that the current push for installing computerized physician order entry systems nationwide [42] [43] [44] [45] would be beneficial in preventing harmful medication errors in the NICU. However, because over half of the errors occurred at the administering stage of medication processing, other interventions such as the smart pump would be useful to reduce these errors. 46 However, caution must be exercised when introducing these devices in the NICU. As shown in this study, faulty equipment and delivery devices for medication administration were associated with harm. Strategies to help reduce this potential for harm need to be explored and can include techniques such as direct observational analyses and simulations. 47, 48 By targeting these risk factors for harm in the NICU, our data suggest that a significant number of errors that occur in this clinical setting could be reduced. 
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